Physician profile
Michael E Clevenger
NPI 1245230341
$7,611.14
in general payments reported to CMS, 2019-2025
44 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,613 · 2020: $1,643 · 2021: $2,046 · 2022: $1,124 · 2023: $493 · 2024: $180 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $794.56 | 2019-2025 | Uplizna, Aimovig |
| Biogen, INC. | $742.87 | 2019-2025 | Vumerity |
| Genzyme Corporation | $724.66 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $528.46 | 2019-2025 | |
| Abbvie INC. | $501.73 | 2021-2025 | Qulipta, Ubrelvy |
| Ucb, INC. | $478.68 | 2019-2025 | Briviact, Nayzilam |
| Kyowa Kirin, INC. | $427.00 | 2020-2022 | |
| Emd Serono, INC. | $414.14 | 2019-2020 | |
| Sk Life Science, INC. | $338.81 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $273.84 | 2019-2025 | Ultomiris |
| Allergan, INC. | $239.38 | 2019-2022 | |
| Lilly USA, LLC | $213.38 | 2019-2023 | Reyvow, Emgality |
| Genentech USA, INC. | $192.19 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $190.15 | 2019-2024 | Rytary |
| Sunovion Pharmaceuticals INC. | $187.09 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Clevenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.